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Summary and Discussion  
Classical Hodgkin lymphoma (cHL) is a B cell lymphoma characterized by a minority 
of malignant Hodgkin Reed-Sternberg (HRS) cells that are located within a vast 
majority of inflammatory cells. These reactive cells provide a microenvironment that 
supports survival and growth of HRS cells. 
HRS cells are derived from germinal center B cells that have lost their B cell 
phenotype including expression of the immunoglobulin genes1. Although normal 
germinal center B cells that lack functional immunoglobulin undergo apoptosis, HRS 
cells can escape this programmed cell death2, 3. Besides the constitutive activation of 
NF-κB and the JAK/STAT signaling pathways which both are hallmarks of cHL, HRS 
cells also show aberrant activity of multiple receptor tyrosine kinases (RTKs) that are 
not normally expressed by B cells4. These factors all contribute to survival and 
proliferation of HRS cells. 
In this thesis, the expression and relevance of known and novel players in the 
pathogenesis of cHL were studied to explore novel survival mechanisms employed by 
HRS cells and novel anti-tumor escape mechanisms. 
Insulin-like growth factor 1 receptor is a prognostic factor in cHL  
The insulin-like growth factor-1 receptor (IGF-1R) is a RTK that has been implicated in 
many malignancies and plays a crucial role in proliferation, transformation, apoptosis 
protection and chemotherapy-resistance5,6. In chapter 2, we evaluated the expression, 
prognostic significance and functionality of IGF-1R in cHL and studied the IGF-1R 
signaling pathway in cHL cell lines.  
Overall, IGF-1R was expressed in 55% of the cHL patients. The percentage of IGF-1R 
positivity was much higher in the nodular sclerosis subtype of cHL (38/61 cases) as 
compared to the mixed-cellularity subtype (1/9 cases). The 5-years progression-free 
survival (PFS) was 93% in the IGF-1R positive patient group, which was significantly 
higher than the 5-years PFS in the IGF-1R negative patients (77%, p=0.047). We 
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observed marked differences in IGF-1R levels in three cHL cell lines, with the highest 
levels observed for L428 cells. The levels of IGF-1 in cell culture supernatant of these 
three cell lines were similar. IGF-1 treatment had the most prominent effect on the 
proliferation of L428 cells. Thus L428 cells were most sensitive to IGF-1 treatment, 
consistent with its high IGF-1R expression level. After 72 hours of treatment with the 
IGF-1 inhibitor picropodophyllin (PPP), both the viability and proliferation decreased in 
all 3 cHL cell lines. The strongest effects were again observed for L428 cells. 
Treatment with PPP induced a marked increase in the G2/M cell population in all three 
cell lines, indicating an effective G2/M cell cycle arrest. Consistent with other cancer 
cell lines, we observed enhanced phosphorylation of IGF-1R, AKT and ERK1/2 levels 
upon stimulation with IGF-1. PPP treatment in L428 decreased IGF-1R 
phosphorylation and AKT phosphorylation, while ERK phosphorylation was 
upregulated. These findings are similar to the results previously reported in melanoma 
cell lines7. The proposed mechanism behind the enhanced ERK phosphorylation is 
that PPP induces ubiquitination of IGF-1R which in turn activates ERK1/27. PPP also 
decreased phosphorylation of CDC2 (Thr14/Tyr15) and induced cyclinB1 expression, 
which is consistent with the observed G2/M-phase cell cycle arrest.  
To explain the unexpected discrepancy between the enhanced survival in IGF-1R 
positive patients and the favorable effect of IGF-1 stimulation, additional functional 
studies are required. Previous studies revealed that low IGF-1R expression is 
associated with de-differentiation of various human cancers8-11. In some cancers, the 
p53 inhibiting oncogene MDM2 downregulates IGF-1R and is associated with a more 
malignant phenotype12. So, IGF-1R negative HRS cells might be more aggressive 
than IGF-1R positive HRS cells. Another explanation might be related to anti-tumor 
immune responses of the reactive cells. The IGF-1/IGF-1R pathway plays important 
roles in hematopoietic cell growth, differentiation and normal immune functioning13. 
Activated T cells have been shown to be more sensitive to IGF-1 and proliferate more 
after the addition of IGF-114. So, if increased IGF-1R expression in tumor cells 
indicates increased presence of IGF-1 in the microenvironment, this could imply 
stronger anti-tumor immune responses.  
Chapter 7 
120 
Expression patterns of the Ephrin family members in HL 
The Ephrin family is the largest RTK family and it is of increasing interest in cancer 
research in recent years. We investigated expression of the Ephrin family members in 
HL in chapter 3. At the mRNA level 17 of the 21 Ephrin family members were 
detectable in at least one of the eight HL cell lines. In total tissue samples of 2 cHL 
and 2 nodular lymphocyte predominant (NLP) HL cases several family members were 
found to be expressed, indicating that cells in the microenvironment also express 
Ephrin family members. 
We next analyzed five Ephrin family members (EphA1, EphA3, ephrin-A3, ephrin-A4 
and ephrin-B1) by immunohistochemistry. A different expression pattern in primary 
tissue was observed between NLPHL and cHL. In NLPHL, EphA3, ephrin-A4 and 
ephrin-B1 were expressed in all cases, EphA1 in part of the cases while ephrin-A3 
was not expressed. In cHL, EphA3, ephrin-A3, ephrin-A4 and ephrin-B1 were 
detected in a high percentage of cases, whereas EphA1 was negative in all cases. 
Overall, we showed that the Ephrin family is widely expressed in the tumor cells in HL, 
while some family members with tumor suppressor function, like EpHA7, are lost in 
the cell lines. This is similar to other germinal center derived lymphomas including 
follicular lymphoma, Burkitt lymphoma and germinal center B cell like diffuse large B 
cell lymphoma15, since normal germinal center B cells express EphA7. Further 
support of a potential tumor suppressor role of EphA7 in follicular lymphomas are the 
occurrence of hemizygous 6q deletions including the EphA7 gene locus on 6q19 and 
methylation of the promoter region caused loss of EphA7 expression15. In Sezary 
syndrome, a T cell leukemia, missense mutations have been found in EphA716. 
Besides expression in tumor cells, we found EphA3, ephrin-A4 and ephrin-B1 positive 
cells in the microenvironment of cHL, and EphA1 expression on the infiltrating 
lymphocytes surrounding the tumor cells in NLPHL. These results suggest that there 
is a potential role for the Ephrin family in HL pathogenesis. 
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The role of Toll-like receptors in the pathogenesis of human B cell 
lymphomas 
Toll-like receptors (TLRs) initiate the first line of defense against microbial infection by 
recognition of pathogen associated molecular patterns. They activate innate immunity 
and modulate adaptive immune responses. In chapter 4 we review recent findings on 
the role of TLRs in the pathogenesis of B cell lymphomas and discuss their 
involvement in malignant transformation, tumor progression and immune evasion 
processes. Long-term triggering of the TLRs may lead to somatic mutations by 
chronic activation of naive B cells or by induction of an inflammatory 
microenvironment that favors induction of mutations. Secondly, TLRs can favor 
survival of precursor cells by increasing proliferation and inhibiting apoptosis through 
activation of the NF-κB pathway. Finally, malignant B cells can induce an immune 
suppressive microenvironment through stimulation of specific TLRs on reactive 
infiltrating cells. It has become clear that TLRs have a role in the transformation 
process of B cell lymphomas originating from marginal zone and follicular cells17,18. 
For other types of B cell lymphomas, as multiple myeloma and chronic lymphocytic 
leukemia, TLRs probably participate in immune evasion and tumor progression19-22. 
The role of TLRs in normal B cells has indicated them as potential therapeutic targets. 
Agonists have been used as adjuvants or vaccines to stimulate anti-tumor immune 
responses in vivo23-27.  
In chapter 5, we analyzed the expression of TLRs in 8 cHL cell lines and primary cHL 
tissue samples. Expression of TLR1, TLR2, TLR6, TLR7, TLR9 and TLR10 was 
detected at the mRNA level in all cell lines, at variable levels. TLR4 and TLR9 were 
expressed in the tumor cells in a large proportion of the cHL cases. Ligation of TLR4 
might be associated with damage associated molecular patterns such as HSP60, 
which is expressed in HL28, while ligation of TLR9 might be associated with the 
presence of Epstein Barr virus (EBV). Responsiveness of the cHL cell lines to TLR7 
and TLR9 ligation was limited. Expression of TLRs in B cells and B cell malignancies, 
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including HL, has important functional roles in differentiation and pathogenesis. 
Immune escape strategies in Epstein Barr virus associated cHL and 
undifferentiated nasopharyngeal carcinoma 
EBV has been implicated in the development of multiple cancer types, such as 
Hodgkin lymphoma, Burkitt lymphoma and undifferentiated nasopharyngeal 
carcinoma (NPC). In cHL, EBV is present in the tumor cells of 30 to 60% of the cases 
and the frequency is dependent on race and geographical area29. In NPC, which has 
a high incidence especially in South East Asia, EBV is present in all cases30. In both 
cancer types, a latency type II infection pattern is observed, with expression of latent 
membrane protein (LMP)1, LMP2 and EBV nuclear antigen (EBNA)1. 
Despite the restricted set of EBV proteins expressed in both cancer types, escape 
from host anti-tumor immune responses is necessary for the tumor cells to survive. 
Tumor cells can use different immune escape mechanisms with loss of HLA class I 
and HLA class II expression being one of the most commonly applied mechanisms in 
the pathogenesis of EBV associated cancer. Another mechanism involves retention of 
the class II-associated invariant chain peptide (CLIP) in the antigen binding cleft of 
HLA class II preventing binding of other antigenic peptides. In the endosomes, 
HLA-DM promotes the dissociation of the CLIP peptide (a place-keeper peptide) from 
HLA class II, which allows antigenic peptides to bind. HLA-DO is a non-classical HLA 
protein that forms a stable complex with HLA-DM and inhibits HLA-DM function31-33.  
In chapter 6, we addressed the question which immune escape mechanisms are 
applied by the tumor cells of these two cancer subtypes. We studied expression of 
HLA class I, CLIP, HLA-DM and HLA-DO in a selection of HLA class II positive cHL 
patients. In NPC patients, we studied expression of HLA class I, HLA class II, HLA-DM 
and HLA-DO. About half of the HLA class II+ cHL cases stained positive for HLA class 
I. In a subset of the HLA class II+ cHL patients, absence of HLA-DM was associated 
with retention of CLIP in the HLA class II peptide-binding groove, preventing 
presentation of antigenic peptides derived from amongst others EBV. HLA-DO, which 
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probably interferes with the function of HLA-DM, is normally only expressed in B cells. 
However, expression of HLA-DO was not related to the presence of CLIP or 
expression of HLA-DM in cHL. Retention of CLIP in HLA class II molecules provides 
an alternative mechanism to escape from an anti-tumor response. In NPC patients 
downregulation of HLA class I was found in 2 out of 11 cases and HLA class II 
expression was lost in part of the tumor cells in half of the cases. Levels of HLA-DM 
and HLA-DO correlated with each other as well as with HLA class II expression, 
suggesting that HLA-DO interferes with the function of HLA-DM. So, in HL absence of 
HLA-DM was associated with CLIP expression and HLA-DO did not seem to play a 
role. In contrast, in NPC HLA-DM and HLA-DO were both expressed, probably 
providing a different mechanism to block HLA class II function. 
Overall conclusion: New insights into tumor cell survival 
strategies and escape from anti-tumor immune responses 
Combination of data in these chapters shows involvement of some new players in 
survival of HRS cells and their escape from anti-tumor immune responses. In addition 
to known pathways that are aberrantly activated in HRS cells (see chapter 1), 
aberrant expression of IGF-1R, Ephrin family members and TLRs might provide 
additional signals leading to survival and growth of the tumor cells. Despite the 
oncogenic effect of IGF-1R in cell lines, IGF-1R expression in HRS cells predicts a 
favorable outcome. The wide expression of Ephrin family members both in the tumor 
cells and the microenvironment suggests that there is a role for the Ephrin family in HL. 
Similarly, the wide expression of TLRs in HRS cells also supports a role in HL 
pathogenesis, although the effect of TLR triggering on HL cell lines was limited. 
In terms of immune escape, potential mechanisms involve lack of functional antigen 
presentation and aberrant expression of TLRs. Mechanisms related to HLA include 
downregulation of HLA class I and II, and retention of CLIP in HLA class II molecules 
impairing antigen presentation in cHL. In NPC, HLA class I and II downregulation was 
observed in part of the cases. There was a strong correlation of HLA class II 
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expression with HLA-DO and HLA-DM expression, suggesting that HLA-DO interferes 
with HLA-DM function leading to expression of CLIP and impaired antigen 
presentation.  
Future perspectives 
A main drawback in functional HL studies is the lack of an appropriate mouse model. 
With the availability of newer immune deficient mice models such as Rag2−/−Jak3−/− 
Balb/c mice34，or NOD/SCID/gamma(null) (NOG) mice35 that are  humanized easier36, 
it might become feasible to set up a good mouse model for HL. A good model should 
have HRS cells and a microenvironment that supports tumor cell growth and that can 
be modulated to alter anti-tumor immune responses.   
The first step to further explore the potential in vivo interaction loop of the 
IGF-1/IGF-1R pathway in HL is to stain HL tissue samples for IGF-1 and determine 
expression patterns in both HRS cells and reactive cells. Next, it is important to 
determine the phosphorylation status of IGF-1R in primary tumor cells. Although 
tyrosine phosphorylation staining on tissue samples is difficult, it might be worthwhile 
to set this up to further support the role of IGF-1R in HL. To verify the proliferative 
activity of IGF-1R in vivo, a double staining for IGF-1R and Ki-67 and for 
phosphorylated IGF-1R and Ki-67 could be done, to demonstrate that IGF-1R positive 
HRS cells indeed are actively proliferating cells. To better understand the functionality 
of the IGF-1 pathway, we should test the effect of IGF-1R knockdown or IGF-1 
neutralizing antibody on growth of HL cell lines. 
We showed that IGF-1R is a negative prognostic factor in HL. This finding should be 
validated in an independent patient cohort. It might be of interest to also study the 
prognostic effect of phosphorylated IGF-1R. If validated, IGF-1R expression at 
diagnosis may be incorporated in current risk stratification systems to improve the 
distinction between favorable and unfavorable prognostic subgroups. As the 
IGF-1/IGF-1R pathway plays important roles in hematopoietic cell growth and 
differentiation, it can be anticipated that the IGF-1R pathway also affects the reactive 
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cells in the microenvironment. This could be studied by co-culturing naïve T cells with 
HRS cells with or without presence of IGF-1 or IGF-1 neutralizing antibody37.  
EphA7 is one of the members of the Ephrin family that has tumor suppressor 
functions. In HL, the possible mechanisms for loss of EphA7 are largely unknown. 
Deletions of 6q19 are not common in HL, although loss of the 6q21-27 has been 
reported in 1 out of 9 cases38 and 21% of cases39. Hypermethylation of EphA7 was 
more pronounced in primary mediastinal large B cell lymphoma as compared to HL40. 
Mutations of EphA7 were not found in HL cell lines in a study applying whole exome 
sequencing41.  
It will be a challenge study the functional role of the Ephrin family in HL cell lines upon 
inhibition or knock down of specific Eph-receptors or ephrin ligands. This is due to the 
complex interactions with multiple ligands that can bind to the same receptor and all 
ligands being able to bind to several receptors. To circumvent this problem, the use of 
small inhibitors targeting multiple members at the same time would present an 
attractive approach. 
For the TLRs, our analysis on primary tissue samples is still incomplete due to lack of 
good antibodies. In HL, the possible association with NF-κB activations needs to be 
further resolved. Functional studies of TLRs in cHL cell lines might not represent a 
good model to study the in vivo relevance since in the cell lines, the tumor cells are 
independent of the microenvironment. To clarify the in vivo function of TLRs, 
functional studies should be performed on sorted primary tumor cells or in an animal 
model. Both approaches are challenging as primary tumor cells are not very viable in 
culture and an animal model is not available yet.  
To further establish immune escape mechanisms in EBV positive cancers, we can 
analyze CLIP, HLA class II, HLA-DM, and HLA-DO expression in HRS cell lines using 
flow cytometry. This will provide further quantitative data with respect to the 
expression levels of these genes. Unfortunately, there is only one EBV+ HL cell line, 
and the tumor cell derived origin is uncertain. To further explore a potential role we 
can overexpress LMP1, LMP2 or EBNA1 in the EBV- HL cell lines and determine the 
ability of these tumor cells to present these peptides using tetramers. We can 
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measure the expression of membranous CLIP upon HLA-DM knock out or HLA-DO 
overexpression. In this way we can unravel the strategy that tumor cells apply to 
escape immune surveillance.  
Antigen presentation by HLA class II could potentially result in a different cellular 
background in the HL microenvironment in comparison to HLA class II negative cases. 
This may be reflected by the number and activation state of T helper cells and by 
cytokine production. It is important to include CLIP analysis in these experiments, as 
HRS cells with CLIP and HLA class II expression should be regarded as being not 
functional and in these cases a pattern similar to HLA class II negative cases is 
anticipated. It is also possible to overexpress HLA-DM in a HL cell line and co-culture 
the cell with naïve T cells to analyze the effect on the differentiation into Tregs and 
cytotoxic CD4 cells42. As HLA class II expression is a prognostic marker in HL43, it is of 
interest to study the difference of membranous CLIP positive and negative cases on 
the prognosis of HL patients. In NPC the expression of HLA class II, HLA-DM and 
HLA-DO should also be coupled to prognosis. Moreover, frozen material should be 
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